Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)

A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease

Primary Objective:

To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa.

Secondary Objective:

To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).

Study Overview

• Status: Completed
• Conditions: Glycogen Storage Disease Type II;Pompe's Disease
• Intervention / Treatment: Drug: Avalglucosidase alfa (GZ402666); Drug: Alglucosidase alfa (GZ419829)

Detailed Description

The duration of the study per participant will be up to approximately 6 years that will consist of a 14-day screening period (may be extended up to 8 weeks in pre-specified situations), a 49-week blinded treatment period (except for the subgroup of pediatric patients aged 3 to less than (<) 18 years enrolling directly in the open-label long-term follow-up phase), a 240-week open-label treatment period, and a 4-week post-treatment observation period.

• Study Type: Interventional
• Enrollment (Actual): 101
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Caba, Argentina, C1181ACH
    • Investigational Site Number 0320001
• Australia
  • Auchenflower, Australia, 4066
    • Investigational Site Number 0360001
• Austria
  • Wien, Austria, 1090
    • Investigational Site Number 0400001
• Belgium
  • Bruxelles, Belgium, 1070
    • Investigational Site Number 0560003
  • Leuven, Belgium, 3000
    • Investigational Site Number 0560001
• Brazil
  • Brasilia, Brazil, 71625-009
    • Investigational Site Number 0760004
  • Sao Paulo, Brazil, 04037-002
    • Investigational Site Number 0760001
• Canada
  • Hamilton, Canada, L8N 3Z5
    • Investigational Site Number 1240003
  • Montreal, Canada, H3A 2B4
    • Investigational Site Number 1240002
• Czechia
  • Praha 2, Czechia, 12808
    • Investigational Site Number 2030001
• Denmark
  • København Ø, Denmark, 2100
    • Investigational Site Number 2080003
• France
  • Angers, France, 49933
    • Investigational Site Number 2500008
  • Bordeaux, France
    • Investigational Site Number 2500007
  • Brest Cedex 2, France, 29609
    • Investigational Site Number 2500011
  • Bron, France, 69677
    • Investigational Site Number 2500004
  • Clermont Ferrand, France, 63003
    • Investigational Site Number 2500010
  • Lille, France, 59037
    • Investigational Site Number 2500005
  • Marseille Cedex 5, France, 13385
    • Investigational Site Number 2500006
  • Paris, France, 75013
    • Investigational Site Number 2500001
• Germany
  • Bochum, Germany, 44789
    • Investigational Site Number 2760006
  • Mainz, Germany, 55131
    • Investigational Site Number 2760001
  • München, Germany, 80336
    • Investigational Site Number 2760003
  • Münster, Germany, 48149
    • Investigational Site Number 2760002
• Hungary
  • Budapest, Hungary, 1083
    • Investigational Site Number 3480001
• Italy
  • Brescia, Italy, 25123
    • Investigational Site Number 3800006
  • Messina, Italy, 98125
    • Investigational Site Number 3800001
  • Milano, Italy, 20122
    • Investigational Site Number 3800002
  • Napoli, Italy, 80131
    • Investigational Site Number 3800007
  • Torino, Italy, 10126
    • Investigational Site Number 3800003
• Japan
  • Kodaira-Shi, Japan
    • Investigational Site Number 3920002
• Korea, Republic of
  • Seoul, Korea, Republic of, 03080
    • Investigational Site Number 4100001
  • Seoul, Korea, Republic of, 06273
    • Investigational Site Number 4100002
• Mexico
  • Mexico, Mexico
    • Investigational Site Number 4840001
• Netherlands
  • Rotterdam, Netherlands, 3015 GE
    • Investigational Site Number 5280001
• Poland
  • Warszawa, Poland, 02-097
    • Investigational Site Number 6160001
• Portugal
  • Braga, Portugal, 4710-243
    • Investigational Site Number 6200001
• Russian Federation
  • Moscow, Russian Federation, 125367
    • Investigational Site Number 6430001
• Spain
  • Barcelona, Spain, 08025
    • Investigational Site Number 7240002
  • Barcelona, Spain, 08950
    • Investigational Site Number 7240003
• Switzerland
  • Zürich, Switzerland, 8091
    • Investigational Site Number 7560002
• Taiwan
  • Taipei, Taiwan, 10043
    • Investigational Site Number 1580001
• Turkey
  • Ankara, Turkey, 06100
    • Investigational Site Number 7920001
  • Istanbul, Turkey, 34390
    • Investigational Site Number 7920002
• United Kingdom
  • Birmingham, United Kingdom, B15 2GW
    • Investigational Site Number 8260005
  • Cambridge, United Kingdom, CB2 OQQ
    • Investigational Site Number 8260002
  • London, United Kingdom, NW3 2QG
    • Investigational Site Number 8260001
  • Newcastle Upon Tyne, United Kingdom, NE1 4LP
    • Investigational Site Number 8260004
  • Salford, United Kingdom, M6 8HD
    • Investigational Site Number 8260003
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85013
      • Investigational Site Number 8400015
  • California
    • Los Angeles, California, United States, 90095
      • Investigational Site Number 8400020
    • Orange, California, United States, 92868
      • Investigational Site Number 8400011
    • Stanford, California, United States, 94305
      • Investigational Site Number 8400017
  • Florida
    • Gainesville, Florida, United States, 32610
      • Investigational Site Number 8400016
  • Georgia
    • Decatur, Georgia, United States, 30033
      • Investigational Site Number 8400007
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Investigational Site Number 8400023
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Investigational Site Number 8400002
  • Kansas
    • Kansas City, Kansas, United States, 66160-7321
      • Investigational Site Number 8400012
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Investigational Site Number 8400010
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Investigational Site Number 8400001
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Investigational Site Number 8400019
  • New York
    • Great Neck, New York, United States, 11020
      • Investigational Site Number 8400026
    • Valhalla, New York, United States, 10595
      • Investigational Site Number 8400008
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Investigational Site Number 8400006
  • Ohio
    • Cincinnati, Ohio, United States, 45267-0542
      • Investigational Site Number 8400009
  • Oregon
    • Portland, Oregon, United States, 97239
      • Investigational Site Number 8400014
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Investigational Site Number 8400025
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • Investigational Site Number 8400018
  • Virginia
    • Fairfax, Virginia, United States, 22030
      • Investigational Site Number 8400005
  • West Virginia
    • Morgantown, West Virginia, United States, 26506
      • Investigational Site Number 8400024

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria :

• The participant has confirmed acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or 2 confirmed GAA gene mutations.
• The participant must provide signed, informed consent prior to performing any study related procedures. Consent of a legally authorized guardian(s) is (are) required for legally minor participant as defined by local regulation. If the participant is legally minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from participants, if applicable.

Exclusion criteria:

• The participant is <3 years of age.
• The participant has known Pompe specific cardiac hypertrophy.
• The participant is wheelchair dependent.
• The participant is not able to ambulate 40 meters (approximately 130 feet) without stopping and without an assistive device.
• The participant requires invasive-ventilation (non-invasive ventilation is allowed).
• The participant is not able to successfully perform repeated forced vital capacity (FVC) measurements in upright position of greater than or equal to 30% predicted and less than or equal to 85% predicted.
• The participant (and participant's legal guardian if participant is legally minor as defined by local regulation) is (are) not able to comply with the clinical protocol.
• The participant has had previous treatment with alglucosidase alfa or any investigational therapy for Pompe disease.
• The participant has prior or current use of immune tolerance induction therapy.
• The participant, if female and of childbearing potential, has a positive pregnancy test (beta-human chorionic gonadotropin) at baseline.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: avalglucosidase alfa (GZ402666); Administered intravenously every 2 weeks	Drug: Avalglucosidase alfa (GZ402666); Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Active Comparator: alglucosidase alfa (GZ419829); Administered intravenously every 2 weeks	Drug: Alglucosidase alfa (GZ419829); Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous; Other Names: Myozyme; Lumizyme

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49	FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Least square (LS) mean and standard error (SE) were derived from mixed model for repeated measure (MMRM) model with baseline FVC [percent (%) predicted, as continuous], sex, age (in years at baseline), treatment group, visit, interaction term between treatment group and visit as fixed effects. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100. After non-inferiority (NI) testing, a test for superiority of avalglucosidase alfa versus alglucosidase alfa was performed with an overall 2-sided 5% level of significance.	Baseline, Week 49

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PAP: Change From Baseline in Total Distance Walked During Six-minute Walk Test (6MWT) at Week 49	6MWT was a standardized test that measured the distance (in meters) covered by the participant by walking on a flat, hard surface in a period of a 6-minute walk. Mean distance walked gives an indication of functional endurance. The greater the distance (that a participant could walk in 6 minutes), the greater the endurance. LS mean and SE were derived from MMRM model with baseline FVC (% predicted) and baseline 6MWT (distance walked in meter), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Change From Baseline in Percent Predicted Maximal Inspiratory Pressure (MIP) in Upright Position at Week 49	MIP is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible. LS mean and SE were derived from MMRM model for MIP % predicted adjusted for MIP % predicted at baseline, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Change From Baseline in Percent Predicted Maximal Expiratory Pressure (MEP) in Upright Position at Week 49	MEP is a quick and non-invasive test to measure strength of expiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MEP is the greater pressure generated during maximal expiration. LS mean and SE were derived from MMRM model for MEP % predicted adjusted for MEP % predicted at baseline, age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Change From Baseline in Quick Motor Function Test (QMFT) Total Scores at Week 49	The QMFT was an observer administered test to evaluate changes in motor function. QMFT comprised of 16 items specifically difficult for participants with Pompe disease. Each item was scored separately on a 5-point ordinal scale (ranged from 0 to 4, higher score indicated better outcome). Total QMFT score was obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function), higher score represented better outcome. LS mean and SE were derived from MMRM models adjusted for total QMFT score at baseline, baseline FVC (% predicted), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Change From Baseline in Lower Extremity Muscle Strength at Week 49 as Assessed by Hand-Held Dynamometry (HHD)	HHD: a portable method for strength quantitation. To complete a make test, participant exerted maximal force against dynamometer with gradual increase in force and completed isometric hold for 4-5 seconds. Muscle strengths were collected in Newton. Every muscle group (hip: flexion, extension, abduction; knee: flexion, extension and ankle dorsiflexion) were measured 2 times and highest value was reported. Summary score was sum of 12 measurements (2 measurements per muscle group) from 6 muscle groups on each side (left and right). An increase from Baseline was reflective of increased muscle strength, whereas a decrease from Baseline was reflective of decreased muscle strength. LS mean and SE were derived from MMRM model for HHD lower extremity muscle strength composite score adjusted for summary HHD lower extremity score at baseline, baseline FVC (% predicted), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Change From Baseline in 12-Item Short-Form Health Survey (SF-12): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Week 49	SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, PCS and MCS. The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life. LS mean and SE were derived from MMRM models adjusted for baseline score (PCS or MCS), baseline FVC (% predicted), age (in years, at baseline), gender, treatment group, visit, and treatment-by-visit interaction as fixed effects.	Baseline, Week 49
PAP: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Infusion-Associated Reactions (IARs)	AE: any untoward medical occurrence in participant who took study drug and not necessarily have to had causal relationship with treatment. TEAEs: AEs that developed/worsened in grade/became serious during TEAE period in PAP (from time of 1st treatment date to last treatment date+4 weeks for participants who didn't receive any treatment in open-label or to time just prior to 1st treatment in open-label for participants who received treatment in open-label). Protocol-defined IARs: AE of special interest (AESIs) that occurred during either infusion/observation period following infusion which were deemed to be related/possibly related to study drug. Algorithm-defined IARs: any TEAE meeting either 1 of 2 criteria: 1) event occurred from start to end of infusion + 24 hours, considered related to study drug, 2) If AE time component missed, compare AE start date with infusion start and end date. If AE start date was between infusion start and end date + 1 day and it was related to study drug.	From Baseline up to Week 49
Open-label Period: Number of Participants With TEAEs and IARs	AE: any untoward medical occurrence in a participant who received study drug and did not necessarily have to had a causal relationship with treatment. TEAEs in open-label: AEs that developed/worsened in grade/became serious during TEAE period in open-label (from time of 1st open-label treatment to last treatment date + 4 weeks). Protocol-defined IARs: defined as AESIs that occurred during either infusion/observation period following infusion which were deemed to be related/possibly related to study drug. Algorithm-defined IARs: any TEAE meeting either 1 of 2 criteria: 1) event occurred from start to end of infusion plus 24 hours, considered related to study drug, 2) If AE time component missed, compare AE start date with infusion start and end date. If AE start date was between infusion start and end date plus 1 day and it was related to study drug.	Week 50 to 289 in open-label long-term period
PAP: Percentage of Participants With Treatment-Emergent Antidrug Antibodies (ADA) Response	ADA response categories: 1) Treatment-induced: ADAs developed following administration of the study drug. If the baseline ADA sample was missing or non-reportable and at least one reportable on-treatment ADA sample was available, the baseline sample was considered as "negative". 2) Treatment-boosted: Pre-existing ADAs that were boosted at least two titer steps from baseline (i.e., 4 fold increase in titers) following administration of the study drug (any time after the first drug administration). 3) Treatment emergent: combination of treatment induced and treatment boosted.	From Baseline up to Week 49

Collaborators and Investigators

• Sponsor: Genzyme, a Sanofi Company
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

General Publications

• Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Erratum In: Lancet Neurol. 2022 Apr;21(4):e4.

Study record dates

Study Major Dates

• Study Start (Actual): November 2, 2016
• Primary Completion (Actual): March 19, 2020
• Study Completion (Actual): May 31, 2023

Study Registration Dates

• First Submitted: May 23, 2016
• First Submitted That Met QC Criteria: May 23, 2016
• First Posted (Estimated): May 25, 2016

Study Record Updates

• Last Update Posted (Actual): April 4, 2024
• Last Update Submitted That Met QC Criteria: March 29, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Lysosomal Storage Diseases, Nervous System; Glycogen Storage Disease Type II; Glycogen Storage Disease
• Other Study ID Numbers: EFC14028; 2016-000942-77 (EudraCT Number); U1111-1178-4806 (Other Identifier: WHO universal trial number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No